Tysabri Resubmission: Early Safety Test For New Commissioner
Executive Summary
The potential market re-entry for the multiple sclerosis therapy Tysabri (natalizumab) is likely to be one of the most high-profile safety issues facing the FDA under new leadership over the next six months
You may also be interested in...
Rituxan Launch For Arthritis, Tysabri Return Expected In Mid-’06, Biogen Says
Biogen Idec could launch Rituxan (rituximab) for rheumatoid arthritis and relaunch Tysabri (natalizumab) for multiple sclerosis by mid-2006, CFO Peter Kellogg said during an Oct. 26 earnings call
Rituxan Launch For Arthritis, Tysabri Return Expected In Mid-’06, Biogen Says
Biogen Idec could launch Rituxan (rituximab) for rheumatoid arthritis and relaunch Tysabri (natalizumab) for multiple sclerosis by mid-2006, CFO Peter Kellogg said during an Oct. 26 earnings call
Tysabri Re-Entry Hinges On Effective Risk Management: Diagnostics May Be Key
Any risk management program tied to the market re-entry of Biogen Idec/Elan's Tysabri would likely include diagnostic procedures to test for early signs of progressive multifocal leukoencephalopathy